Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Declines By 7.9%

Immix Biopharma, Inc. (NASDAQ:IMMX) was the recipient of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 400,700 shares, a decline of 7.9% from the October 31st total of 434,900 shares. Based on an average trading volume of 126,100 shares, the short-interest ratio is presently 3.2 days. Approximately 2.5% of the company’s shares are short sold.

Institutional Trading of Immix Biopharma

An institutional investor recently bought a new position in Immix Biopharma stock. Invst LLC acquired a new stake in shares of Immix Biopharma, Inc. (NASDAQ:IMMX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 27,000 shares of the company’s stock, valued at approximately $57,000. Invst LLC owned 0.10% of Immix Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 11.26% of the company’s stock.

Immix Biopharma Stock Performance

Shares of NASDAQ IMMX traded down $0.10 during mid-day trading on Monday, hitting $2.01. The stock had a trading volume of 264,533 shares, compared to its average volume of 182,827. The business has a 50 day moving average price of $1.63 and a two-hundred day moving average price of $1.93. The firm has a market cap of $55.29 million, a P/E ratio of -2.38 and a beta of 0.11. Immix Biopharma has a 1 year low of $1.26 and a 1 year high of $7.75.

Immix Biopharma (NASDAQ:IMMX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.08). Equities research analysts predict that Immix Biopharma will post -0.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Immix Biopharma in a research note on Thursday, October 3rd.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.